Efficacy of antiinflammatory and metabolic bioregulation in complex therapy of chronic pancreatitis with the inflammatory changes of gastroduodenal zone organs
PDF (Русский)
DOCX (Українська)


chronic pancreatitis, antiinflammatory and metabolic bioregulatory therapy, inflammatory lesions of the gastroduodenal zone, comorbidity, exocrine pancreatic insufficiency

How to Cite

Shevchenko, N. O., & Babinets, L. S. (2020). Efficacy of antiinflammatory and metabolic bioregulation in complex therapy of chronic pancreatitis with the inflammatory changes of gastroduodenal zone organs. Herald of Pancreatic Club, 49(4), 59-63. https://doi.org/10.33149/vkp.2020.04.06

Abstract views: 19
PDF Downloads: 6 PDF Downloads: 4


Background. The clinical course of chronic pancreatitis (CP) is characterized by symptomatic polymorphism, which is often associated with comorbidity of CP with other lesions of the gastrointestinal tract. Destructive-inflammatory processes of the upper gastrointestinal tract are very common. Such comorbidity is especially typical for young patients with CP (up to 45 years).

The aim is to study the effectiveness of bioregulatory anti-inflammatory and metabolic therapy based on the dynamics of clinical indices and parameters of exocrine pancreatic function and the condition of the mucous membrane of the gastroduodenal zone of patients with CP.

Materials and methods. We examined 50 patients with CP with exocrine insufficiency in the phase of unstable remission in combination with inflammatory diseases of the mucous membranes of the gastroduodenal zone. Group 1 (28 patients, age 40.25±1.34 years) received conventional treatment (CT) — pure pancreatin enzymes, proton pump inhibitors, antispasmodics or prokinetics (if necessary), enhanced by a step-by-step course of bioregulatory therapy, including parenteral course of anti-inflammatory drug Traumel C 2.2 ml intramuscularly twice a week (e.g., Monday and Thursday) and metabolic Ubiquinone Compositum 2.2 ml intramuscularly twice a week (e.g., Tuesday and Friday) № 5 each drug with the transition for oral administration of Traumel C per 1 tablet 1 hour after meals three times a day for 30 days. 22 patients with CP and concomitant exacerbation in gastroduodenal zone group 2 (age 41.34±1.21 years) received only complex CT.

Results and discussion. A comparative analysis of the dynamics of treatment outcomes in the two study groups showed that almost all clinical signs of the disease, endoscopy and exocrine pancreatic function after treatment in the group using anti-inflammatory and metabolic bioregulatory therapy results were significantly better than in CT group. The mean time to normalization of mucous membranes of gastroduodenal zone in the group with an additional course of bioregulation was 14.4±0.86 days, while in the group of CT — 18.1±0.46 days.

Conclusion. It was proved that the additional inclusion of step-by-step bioregulatory antiinflammatory (Traumel C) and metabolic (Ubiquinone Compositum) therapy according to the proposed scheme to the CT significantly more effectively (p˂0.05–0.001) improved the clinical course of the disease, contributed to the normalization of exocrine pancreatic function, as well as more quickly normalized the condition of the mucous membrane of the gastroduodenal zone — during 14.4±0.86 days, while in the group of CT — during 18.1±0.46 days.

PDF (Русский)
DOCX (Українська)


1. Антигомотоксическая терапия распространенных заболеваний у детей (справочное пособие для врачей). Киев: Книга плюс, 2006. 248 с.
2. Бабінець Л. С., Криськів О. І., Коваль Ю. В., Коцаба Ю. Я., Литвинюк Т. С. Оцінка клінічної симптоматики та загального стану хворих на хронічний панкреатит в амбулаторній практиці. Здобутки клінічної та експериментальної медицини. 2011. С. 8.
3. Бабінець Л. С., Пінкевич З. Я. Клініко-патогенетичне обґрунтування впливу тютюнопаління на клінічний перебіг хронічного панкреатиту. Здоров’я України. 2013. № 4. С. 46–48.
4. Винокурова Л. В. Клинико-патогенетические механизмы развития внешне- и внутрисекреторной недостаточности при хроническом панкреатите : автореф. дисс. … д-ра мед. наук : 14.00.47. Москва, 2009. 24 с.
5. Губергриц Н. Б. Внешнесекреторная недостаточность поджелудочной железы: этиопатогенетические варианты и лечение. Сучасна гастроентерологія. 2013. № 3 (13). С. 24–32.
6. Губергриц Н.Б. Новая международная классификация хронического панкреатита (2007) М–ANNHEIM. Вестник Клуба Панкреатологов. 2008. № 1, T. 2. С. 10–25.
7. Наказ МОЗ України від 13.06.2005 № 271. Клінічний протокол для надання медичної допомоги хворим на хронічний панкреатит.
8. Co G.A., Yadav D., Slivka A. et al. Alcohol and smoking as risk factors in an epidemiology study of patients with chronic pancreatitis. Clin. Gastroenterol. Hepatol. 2011. Vol. 9. P. 266–273.
9. Etmad В., Whitcomb D. С. Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology. 2009. Vol. 120, No 3. Р. 682–707.
10. Inflammation Resolution. Dr. B. Seilheimer & Dr. M. Schultz (May 21, 2019).
11. Rutter K., Ferlitsch A., Sautner T. Hospitalization, frequency of interventions, and quality of life after endoscopic, or conservative treatment in patients with chronic pancreatitis. WJS. 2010. Vol. 34, No 11. P. 2642–2647.
12. Sai J.K., Suyama M., Kubokawa Y., Watanabe S. Diagnosis of mild chronic pancreatitis (Cambridge classification): comparative study using secretin injection–magnetic resonance cholangiopancreatography and endoscopic retrograde pancreatography. World J. Gastroenterol. 2008. Vol. 14, No 8. P. 1218–1221.
13. St. Laurent G., Toma I., Tackett M. et al. AB0080 Differential effects of tr14 versus diclofenac on pro-resolving lipid mediators revealed by rnaseq. Annals of the Rheumatic Diseases. 2018. Vol. 77. P. 1237–1238.
14. Yadav D., Lowenfels A. B. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013. Vol. 144. P. 1252–1261.